Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer

Basit Öğe Kaydı
dc.contributor.authorKöş, Mehmet
dc.contributor.authorHocazade, Cemil
dc.contributor.authorKöş, Fahriye Tuğba
dc.contributor.authorUncu, Doğan
dc.contributor.authorKarakaş, Esra
dc.contributor.authorDoğan, Mutlu
dc.contributor.authorZengin, Nurullah
dc.date.accessioned2020-04-30T23:21:46Z
dc.date.available2020-04-30T23:21:46Z
dc.date.issued2016
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000385060700005en_US
dc.descriptionPubMed: 25720573en_US
dc.description.abstractIt was reported that hematological markers of systemic inflammatory response might be prognostic in various cancer types. We aimed to evaluate the platelet/lymphocyte ratio (PLR) as a prognostic factor and its effect on overall survival in non-small cell lung cancer (NSCLC). Clinicopathological characteristics and basal (pretreatment) PLR of 145 patients with NSCLC were evaluated retrospectively. The preoperative or pretreatment blood count data were obtained from the recorded computerized database. PLR was defined as the absolute platelet count divided by the absolute lymphocyte count. A total of 145 patients were enrolled. Median age was 57 years(range 26-83). Receiver operating characteristic curves for overall survival prediction were plotted to verify the optimum cut-off point for PLR. The recommended cut-off values for PLR was 198.2 with a sensitivity of 65.0 % and a specificity of 71.4 %. Median overall survival was 34.0 (95 % confidence interval (CI) 14.7-53.3) months in the group with low PLR (< 198.2), while it was 11.0 (95 % CI 5.6-16.3) months in the group with high PLR (aeyen 198.2). The difference between the groups was statistically significant (p < 0.0001). Our study supports the view that a high basal PLR is a poor prognostic factor in NSCLC. However, the validity of the cut-off values for PLR identified in our study needs further prospective trials.en_US
dc.identifier.doi10.1007/s00508-015-0724-8en_US
dc.identifier.endpage640en_US
dc.identifier.issn0043-5325
dc.identifier.issn1613-7671
dc.identifier.issue17-18en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage635en_US
dc.identifier.urihttps://doi.org/10.1007/s00508-015-0724-8
dc.identifier.urihttps://hdl.handle.net/20.500.12684/4246
dc.identifier.volume128en_US
dc.identifier.wosWOS:000385060700005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Wienen_US
dc.relation.ispartofWiener Klinische Wochenschriften_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPlatelet lymphocyte ratioen_US
dc.subjectNon-small cell lung canceren_US
dc.subjectPrognosisen_US
dc.titlePrognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung canceren_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
4246.pdf
Boyut:
249.95 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu